Quince acquires Orphai in reverse merger; raises $115M PIPE; appoints Dr. Roberts

Quince Therapeutics, Inc.

Acquisition closed May 18; Quince issued 3.26M shares and 67K Series C Preferred to Orphai holders.
Pre-transaction Quince holders will own ~6.9% post-financing; new Investors hold ~61.2%.
PIPE of $115M via sale of Series C Preferred and warrants; warrants could add ~$72M.
Dr. Brigette Roberts appointed to Board and as Chief of Corporate Affairs; salary $600K.
Retention bonuses of $700K for CEO Dirk Thye and $500K for COO Brendan Hannah, contingent on stockholder approval.

item 1.01item 5.03item 2.01item 3.02item 5.02item 7.01item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Appointed

Brigette Roberts

Director

QNCX · Quince Therapeutics, Inc.

Effective: 2026-05-18
Filed: May 18, 2026 13:33 UTC

Brigette Roberts, M.D., was appointed to the Board as a Class III director.

Appointed

Brigette Roberts

Chief of Corporate Affairs

QNCX · Quince Therapeutics, Inc.

Effective: 2026-05-18
Filed: May 18, 2026 13:33 UTC

Dr. Roberts was also appointed as the Chief of Corporate Affairs of the Company.

Source: SEC EDGAR

accession 0001193125-26-228133

view filing index on sec.gov

view primary document

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.